Back to Search
Start Over
PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
- Source :
-
Immunology [Immunology] 2024 Feb; Vol. 171 (2), pp. 224-234. Date of Electronic Publication: 2023 Oct 30. - Publication Year :
- 2024
-
Abstract
- Background: The tumour microenvironment (TME), which is modulated after immune-chemotherapy, is involved in tumour growth and metastasis. Programmed cell death 1 (PD-1) expressed on tumour-infiltrating non-malignant cells plays an important role in the TME through the PD-1/programmed cell death ligand 1 (PD-L1) signalling pathway. However, its impact in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains unclear.<br />Methods: We conducted a retrospective study using tissue samples at relapse for patients with R/R DLBCL (nā=ā45) and evaluated the clinical impact of PD-1 expression on tumour-infiltrating non-malignant cells (microenvironmental PD-1, mPD-1). In addition, corresponding 27 samples at diagnosis were analysed to evaluate the changes in PD-1/PD-L1 expression in the TME after chemotherapy.<br />Results: Patients with mPD-1 <superscript>+</superscript> DLBCL showed significantly better overall survival compared with patients with mPD-1 <superscript>-</superscript> DLBCL (hazard ratio, 0.30, pā=ā0.03). Among patients with mPD-1 <superscript>-</superscript> DLBCL, those positive for neoplastic or microenvironmental PD-L1 (nPD-L1 <superscript>+</superscript> or mPD-L1 <superscript>+</superscript> ) showed significantly worse outcomes. Microenvironmental PD-1 and PD-L1 expression has high correlation at relapse, although none was found at diagnosis.<br />Conclusion: We determined the clinical impact of microenvironmental PD-1 expression and its relationship with neoplastic or microenvironmental expression of PD-L1 in patients with R/R DLBCL. The expression of PD-1 and PD-L1 in the TME dramatically changes during the chemotherapy. Therefore, evaluating TME at relapse, not at diagnosis is useful to predict the outcomes of R/R DLBCL patients.<br /> (© 2023 John Wiley & Sons Ltd.)
- Subjects :
- Humans
Prognosis
Programmed Cell Death 1 Receptor metabolism
Retrospective Studies
Neoplasm Recurrence, Local
Recurrence
Tumor Microenvironment
B7-H1 Antigen metabolism
Lymphoma, Large B-Cell, Diffuse diagnosis
Lymphoma, Large B-Cell, Diffuse drug therapy
Lymphoma, Large B-Cell, Diffuse pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2567
- Volume :
- 171
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 37904615
- Full Text :
- https://doi.org/10.1111/imm.13711